Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methamphetamine is a synthetic, highly addictive central nervous system stimulant belonging to the phenethylamine class. It is structurally related to amphetamine but has greater potency and longer-lasting effects. Methamphetamine increases synaptic concentrations of dopamine, norepinephrine, and serotonin by promoting their release and blocking reuptake in the brain. This results in increased alertness, energy, euphoria, decreased appetite, and enhanced focus. The drug is FDA-approved for the treatment of attention deficit hyperactivity disorder (ADHD) and short-term management of obesity under the brand name Desoxyn; however, most use worldwide is illicit. Methamphetamine can be administered orally (tablet), smoked (crystal form), snorted (powder), or injected (solution). Adverse effects include high addiction potential, cardiovascular complications such as hypertension and arrhythmias, neurotoxicity leading to cognitive deficits with chronic use, psychiatric symptoms including paranoia or psychosis, "meth mouth" due to severe dental decay, insomnia, agitation, hyperthermia at high doses which may be fatal[1][2][4][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methamphetamine.